Zobrazeno 1 - 10
of 88
pro vyhledávání: '"Shantanu Banerji"'
Publikováno v:
Current Oncology, Vol 31, Iss 9, Pp 5498-5515 (2024)
Since the initial US FDA approval of an immune checkpoint inhibitor (ICI) for the treatment of non-oncogene-driven non-small-cell lung cancer (NSCLC) nine years ago, this therapeutic strategy has been cemented as a crucial component of treatment for
Externí odkaz:
https://doaj.org/article/c6a25f9571974d2f9ffe6c77cea1e132
Autor:
Hagit Peretz Soroka, Tushar Vora, Jonathan Noujaim, Nicolas Marcoux, Sarah Cohen‐Gogo, Thierry Alcindor, Caroline Holloway, Caroline Rodrigues, Hatim Karachiwala, Saima Alvi, Ursula Lee, Sylvia Cheng, Shantanu Banerji, Sapna Oberoi, Xiaolan Feng, Alannah Smrke, Christine Simmons, Albiruni Abdul Razak, Abha A. Gupta
Publikováno v:
Cancer Medicine, Vol 12, Iss 18, Pp 18872-18881 (2023)
Abstract Objectives We conducted a retrospective multi‐centre study to assess the real‐world outcome of regorafenib (REGO) and cabozantinib (CABO) in recurrent/refractory bone tumours (BTs) including osteosarcoma (OST), Ewing sarcoma (EWS) and ch
Externí odkaz:
https://doaj.org/article/77f0759b62cf455bb618ca80b59f6638
Autor:
Martin Rupp, Fiorella Fanton-Aita, Stephanie Snow, Paul Wheatley-Price, Barbara Melosky, Rosalyn A. Juergens, Quincy Chu, Normand Blais, Shantanu Banerji, Ryan Ng, Shoghag Khoudigian, Arushi Sharma, Phu Vinh On, Geoffrey Liu
Publikováno v:
Current Oncology, Vol 30, Iss 7, Pp 6559-6574 (2023)
Lorlatinib is the only targeted therapy approved in Canada to treat patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) whose tumor has progressed despite treatment with second-generation ALK tyrosine kinase inh
Externí odkaz:
https://doaj.org/article/7a0dcc0fa9644dafb2573f4dd241ebd7
Autor:
David E. Dawe, Rebekah Rittberg, Iqra Syed, Mary Kate Shanahan, Daniel Moldaver, Oliver Bucher, Katie Galloway, Kayla Reynolds, James T. Paul, Craig Harlos, Julian O. Kim, Shantanu Banerji
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundAlthough therapy for limited-stage small-cell lung cancer (LS-SCLC) is administered with curative intent, most patients relapse and eventually die of recurrent disease. Chemotherapy (CT) with concurrent radiotherapy (RT) remains the standar
Externí odkaz:
https://doaj.org/article/742802ccdef840f4897b65a493687d65
Autor:
Jenny J. Ko, Shantanu Banerji, Normand Blais, Anthony Brade, Cathy Clelland, Devin Schellenberg, Stephanie Snow, Paul Wheatley-Price, Ren Yuan, Barbara Melosky
Publikováno v:
Current Oncology, Vol 30, Iss 4, Pp 3817-3828 (2023)
The PACIFIC trial showed a survival benefit with durvalumab through five years in stage III unresectable non-small cell lung cancer (NSCLC). However, optimal use of imaging to detect disease progression remains unclearly defined for this population.
Externí odkaz:
https://doaj.org/article/7b6122f452f84c648c5e23feebba00b9
Autor:
David E. Dawe, Rebekah Rittberg, Iqra Syed, Mary Kate Shanahan, Daniel Moldaver, Oliver Bucher, Katie Galloway, Kayla Reynolds, James T. Paul, Craig Harlos, Julian O. Kim, Shantanu Banerji
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundExtensive-stage small-cell lung cancer (ES-SCLC) is an incurable cancer with poor prognosis in which characteristics predictive of long-term survival are debated. The utility of agents such as immune checkpoint inhibitors highlights the imp
Externí odkaz:
https://doaj.org/article/d1510321bbbe4dc89a3a88e1c924f9d4
Autor:
Julian O. Kim, Robert Balshaw, Connel Trevena, Shantanu Banerji, Leigh Murphy, David Dawe, Lawrence Tan, Sadeesh Srinathan, Gordon Buduhan, Biniam Kidane, Gefei Qing, Michael Domaratzki, Michel Aliani
Publikováno v:
Cancer & Metabolism, Vol 10, Iss 1, Pp 1-13 (2022)
Abstract Background Metabolomics is a potential means for biofluid-based lung cancer detection. We conducted a non-targeted, data-driven assessment of plasma from early-stage non-small cell lung cancer (ES-NSCLC) cases versus cancer-free controls (CF
Externí odkaz:
https://doaj.org/article/de5caa2bb46646a385eb9236915ff104
Autor:
Diana N. Ionescu, Tracy L. Stockley, Shantanu Banerji, Christian Couture, Cheryl A. Mather, Zhaolin Xu, Normand Blais, Parneet K. Cheema, Quincy S.-C. Chu, Barbara Melosky, Natasha B. Leighl
Publikováno v:
Current Oncology, Vol 29, Iss 7, Pp 4981-4997 (2022)
Non-small cell lung cancer (NSCLC) has historically been associated with a poor prognosis and low 5-year survival, but the use of targeted therapies in NSCLC has improved patient outcomes over the past 10 years. The pace of development of new targete
Externí odkaz:
https://doaj.org/article/1ed9d430c59d4d3496913a7bcdcbbc84
Autor:
Glenwood D. Goss, Johanna N. Spaans, David Huntsman, Timothy Asmis, Natalie M. Andrews Wright, Marc Duciaume, Pardeep Kaurah, Ruth R. Miller, Shantanu Banerji, Harmanjatinder S. Sekhon, Marcio M. Gomes
Publikováno v:
Current Oncology, Vol 29, Iss 5, Pp 3171-3186 (2022)
Inuit are the Indigenous Arctic peoples and residents of the Canadian territory of Nunavut who have the highest global rate of lung cancer. Given lung cancer’s mortality, histological and genomic characterization was undertaken to better understand
Externí odkaz:
https://doaj.org/article/19fa4df936c2416ab987aef3528518a4
Autor:
Ridwan A. Sanusi, Lin Yan, Amani F. Hamad, Olawale F. Ayilara, Viktoriya Vasylkiv, Mohammad Jafari Jozani, Shantanu Banerji, Joseph Delaney, Pingzhao Hu, Elizabeth Wall-Wieler, Lisa M. Lix
Publikováno v:
BMC Public Health, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Diagnosis codes in administrative health data are routinely used to monitor trends in disease prevalence and incidence. The International Classification of Diseases (ICD), which is used to record these diagnoses, have been updated
Externí odkaz:
https://doaj.org/article/770332e40185473db5f409a91ac19e56